Keywords
How to Cite
Abstract
Patients with glioblastoma (GB) rarely survive more than 3 years. This study aimed to analyze clinical characteristics of long-term GB survivors. 69 patients with primary GB who were treated at the A.L. Polenov Neurosurgical Institute since 2009 and had sufficient follow-up were analyzed; survival of 11 of these patients exceeded 3 years, while the remaining 58 failed to achieve this threshold. An immunohistochemical study was performed using Ki-67 and GFAP antibodies. Patients were divided into two groups: the first included 11 patients with a survival rate of more than 3 years, the second (comparison group) with a survival rate of less than 3 years included 58 patients. Long-term survival correlated with the younger patients age (p = 0.002) and tumor response to temozolomide (p = 0.004). Other clinical features, including gender (p = 0.484), Karnovsky status (p = 0.322); tumor location (p = 0.078), volume of the lesion and the number of affected lobes (p = 0.132), the number of surgical interventions (p = 0.278) and the volume of cytoreduction (p = 0.105) were not prognostic in this small patient cohort.References
Горяйнов С.А., Гольдберг М.Ф., Голанов А.В. и др. Феномен длительной выживаемости пациентов с глиобласто-мами. Часть I: роль клинико-демографических факторов и мутации IDH1 (R132H) // Журнал вопросы нейрохирургии им. Н.Н. Бурденко. - 2017. - № 3. - С. 5-16.
Adeberg S., Bostel Т., König L. et all. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? // Radiat Oncol. - 2014. - Vol. 9(1).
Amelot A., De Cremoux P., Quillien V. et all. IDH-Mutation is a weak predictor of long-term survival in glioblastoma patients // PLoS One. - 2015. - Vol. 10(7). - e0130596.
Barbagallo G.M., Paratore S., Caltabiano R. et all. Longterm therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles // Neurosurg Focus. - 2014. - Vol. 37(6). - P. E4.
Bloch O., Han S.J., Cha S. et all. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article // J. Neurosurg. - 2012. - Vol. 117(6). - P 1032-1038.
Burton E.C., Lamborn K.R., Forsyth P. et all. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors // Clin. Cancer Res. - 2002. - Vol. 8(1). - P 180-187.
Chaichana K.L., Garzon-Muvdi Т., Parker S. et all. Supra-tentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients // Ann Surg. Oncol. - 2011. - Vol. 18(1). - P 239-245.
Chaichana K.L., Pendleton C., Chambless L. et all. Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma // J. Clin. Neurosci. - 2013. - Vol. 20(10). - P. 1422-1426.
Feng Y, Wang Z., Bao Z. et all. SOCS3 promoter hyper-methylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients // PLoS One. - 2014. - Vol. 9(3). - e91829.
Field K.M., Rosenthal M.A., Yilmaz M. et all. Comparison between poor and long-term survivors with glioblastoma: review of an Australian dataset // Asia Pac. J. Clin. Oncol. - 2014. - Vol. 10(2). - P 153-161.
Fiore D., Donnarumma E., Roscigno G. et all. miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS // Oncotarget. - 2016. - Vol. 7(15). - P. 19531-19547.
Geisenberger C., Mock A., Warta R. et all. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain // Acta Neuropathol. - 2015. - Vol. 130(3). - P 419-434.
Gerber N.K., Goenka A., Turcan S. et all. Transcriptional diversity of long-term glioblastoma survivors // Neuro Oncol. - 2014. - Vol. 16(9). - P 1186-1195.
Gilbert M.R., Dignam J.J., Armstrong T.S. et all. A randomized trial of bevacizumab for newly diagnosed glioblastoma // N. Engl. J. Med. - 2014. - Vol. 370(8). - P. 699-708.
Glas M., Happold C., Rieger J. et all. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide // J. Clin. Oncol. - 2009. - Vol. 27(8). - P 1257-1261.
Johnson D.R., Leeper H.E., Uhm J.H. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis // 2013. - Vol. 119(19). - P. 3489-3495.
Johnson D.R., Ma D.J., Buckner J.C., Hammack J.E. Conditional probability of long-term survival in glioblastoma: a population-based analysis // Cancer. - 2012. - Vol. 118(22). - P. 5608-5613.
Korshunov A., Sycheva R., Golanov A. Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH) // Acta Neuropathol. - 2006. - Vol. 111(5). - P. 465-474.
Lacroix M., Abi-Said D., Fourney D.R. et all. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival // J. Neurosurg. - 2001. - Vol. 95(2). - P. 190-198.
Martinez R., Schackert G., Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance inglioblastoma multiforme // J. Neurooncol. - 2007. - Vol. 82(2). - P. 133-139.
Martinez R., Schackert G., Yaya-Tur R. et all. Frequent hypermethylation of the DNA repair gene MGMT in longterm survivors of glioblastoma multiforme // J. Neurooncol. - 2007. - Vol. 83(1). - P. 91-93.
Mazaris P., Hong X., Altshuler D. et all. Key determinants of short-term and long-term glioblastoma survival: a 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital // Clin. Neurol. Neurosurg. - 2014. - Vol. 120. - P. 103-112.
McGirt M.J., Chaichana K.L., Gathinji M. et all. Independent association of extent of resection with survival in patients with malignant brain astrocytoma // J. Neurosurg. - 2009. - Vol. 110(1). - P. 156-162.
Millward C.P., Brodbelt A.R., Haylock B. et all. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy // Acta Neurochir (Wien). - 2016. - Vol. 158(10). - P. 1943-1953.
Netsky M.G., August B., Fowler W. The longevity of patients with glioblastoma multiforme // J. Neurosurg. - 1950. - Vol. 7(3). - P. 261-269.
Nomiya T, Nemoto K., Kumabe T. et all. Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases // J. Neurosurg. - 2007. - Vol. 106(4). - P. 575-581.
Oszvald A., G resir E., Setzer M. et all. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age // J. Neurosurg. - 2012. - Vol. 116(2). - P. 357-364.
Reifenberger G., Weber R.G., Riehmer V. et all. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling // Int. J. Cancer. - 2014. - Vol. 135(8). - P. 1822-1831.
Rulseh A.M., Keller J., Klener J. et all. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields // World J. Surg. Oncol. - 2012. - Vol. 10(220).
Sanai N., Polley M.Y., McDermott M.W. et all. An extent of resection threshold for newly diagnosed glioblastomas // J. Neurosurg. - 2011. - Vol. 115(1). - P. 3-8.
Schneider J.P., Trantakis C., Rubach M. et all. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme - a quantitative radiological analysis // Neuroradiology. - 2005. - Vol. 47(7). - P. 489-500.
Scoccianti S., Magrini S.M., Ricardi U. et all. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology) // Neurosurgery. - 2010. - Vol. 67(2). - P. 446-458.
Scott J.N., Rewcastle N.B., Brasher P.M. et all. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study // Ann. Neurol. - 1999. - Vol. 46(2). - P. 183-188.
Shannon S., Vaca C., Jia D. et all. Dexamethasone-me-diated activation of fibronectin matrix assembly reduces dispersal of primary human glioblastoma cells // PLoS One. - 2015. - Vol. 10(8). - e0135951.
Stummer W., Pichlmeier U., Meinel T. et all. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial // Lancet Oncol. - 2006. - Vol. 7(5). - P. 392-401.
Vertosick F.T., Selker R.G. Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis // Surg. Neurol. - 1992. - Vol. 38(5). - P. 359-363.
Weller M., Felsberg J., Hartmann C. et all. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network // J. Clin. Oncol. - 2009. - Vol. 27(34). - P. 5743-5750.
Wen P.Y., Macdonald D.R., Reardon D.A. et all. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group // J. Clin. Oncol. - 2010. - Vol. 28(11). - P. 1963-1972.
Zhang G.B., Cui X.L., Sui D.L. et all. Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients // J. Neurooncol. - 2013. - Vol. 113(2). - P. 251-258.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017